Faeth Therapeutics, Inc. (NASDAQ:FTH) — Market Cap & Net Worth
Market Cap & Net Worth: Faeth Therapeutics, Inc. (FTH)
Faeth Therapeutics, Inc. (NASDAQ:FTH) has a market capitalization of $661.77 Million ($661.77 Million) as of October 12, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10874 globally and #2837 in its home market, demonstrating a -7.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Faeth Therapeutics, Inc.'s stock price $26.03 by its total outstanding shares 25840425 (25.84 Million).
Faeth Therapeutics, Inc. Market Cap History: 2026 to 2026
Faeth Therapeutics, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $672.63 Million to $672.63 Million (0.00% CAGR). Check FTH live share price for real-time trading data and today's change.
Faeth Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Faeth Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see FTH cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of FTH by Market Capitalization
Companies near Faeth Therapeutics, Inc. in the global market cap rankings as of October 12, 2026. See Faeth Therapeutics, Inc. (FTH) balance sheet quality index to understand what proportion of total assets are financed by equity.
Key companies related to Faeth Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
Faeth Therapeutics, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Faeth Therapeutics, Inc.'s market cap moved from $672.63 Million to $ 672.63 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $672.63 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 12th, 2026 the market cap of Faeth Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $661.77 Million USD |
| MoneyControl | $661.77 Million USD |
| MarketWatch | $661.77 Million USD |
| marketcap.company | $661.77 Million USD |
| Reuters | $661.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune chec… Read more